Top-Rated StocksTop-RatedNASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis → Healthcare Takes A Big Step Forward With The Help Of AI (From The Bull Report) (Ad) Free IOVA Stock Alerts $10.74 -0.14 (-1.29%) (As of 01:21 PM ET) Add Compare Share Share Today's Range$10.64▼$11.1850-Day Range$10.88▼$17.1652-Week Range$3.21▼$18.33Volume3.74 million shsAverage Volume8.12 million shsMarket Capitalization$3.01 billionP/E RatioN/ADividend YieldN/APrice Target$24.64 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Iovance Biotherapeutics alerts: Email Address Iovance Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside130.2% Upside$24.64 Price TargetShort InterestBearish22.64% of Float Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.55Based on 22 Articles This WeekInsider TradingAcquiring Shares$2.29 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.40) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.64 out of 5 starsMedical Sector219th out of 2,771 stocksBiological Products, Except Diagnostic Industry19th out of 462 stocks 4.5 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIovance Biotherapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Iovance Biotherapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.64% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Iovance Biotherapeutics has recently increased by 2.20%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 70.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -0.82. Previous Next 2.0 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Iovance Biotherapeutics this week, compared to 6 articles on an average week.Search InterestOnly 53 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 34 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -21% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,287,500.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Iovance Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.40) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -5.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -5.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 4.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Iovance Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressBiden to Drop BOMBSHELL June 13th?Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. About Iovance Biotherapeutics Stock (NASDAQ:IOVA)Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Read More IOVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOVA Stock News HeadlinesMay 13 at 4:00 PM | benzinga.comLooking At Iovance Biotherapeutics's Recent Unusual Options ActivityMay 13 at 11:06 AM | seekingalpha.comIovance Biotherapeutics' Amtagvi: Innovative Therapy, Financial Strain (Rating Downgrade)May 13 at 5:44 AM | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Earns "Buy" Rating from HC WainwrightMay 12 at 4:03 AM | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down to $13.45May 11 at 10:00 AM | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in May 2024May 11 at 6:49 AM | markets.businessinsider.comIovance Biotherapeutics Poised for Growth: Analyst Reiterates Buy Rating Amid Strong Q1 Performance and Promising Clinical AdvancementsMay 11 at 6:49 AM | fool.comIovance Biotherapeutics Reports a Q1 Revenue MissMay 11 at 6:49 AM | msn.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call TranscriptMay 11 at 6:49 AM | finance.yahoo.comIovance Biotherapeutics Inc (IOVA) Q1 2024 Earnings: Aligns with EPS Projections Amidst Strong ...May 10, 2024 | benzinga.comIovance Biotherapeutics's Options: A Look at What the Big Money is ThinkingMay 10, 2024 | seekingalpha.comIovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On AmtagviMay 10, 2024 | fool.comWhy Iovance Stock Is Down 18% TodayMay 10, 2024 | markets.businessinsider.comIovance Biotherapeutics: A Strong Buy on Robust Growth Potential and Early Launch SuccessMay 9, 2024 | investorplace.comIOVA Stock Earnings: Iovance Biotherapeutics Meets EPS, Misses Revenue for Q1 2024May 9, 2024 | sfgate.comIovance Biotherapeutics: Q1 Earnings SnapshotMay 9, 2024 | finance.yahoo.comIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 9, 2024 | globenewswire.comIovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesMay 8, 2024 | americanbankingnews.comIovance Biotherapeutics (IOVA) Set to Announce Quarterly Earnings on ThursdayMay 7, 2024 | americanbankingnews.comInvestors Purchase Large Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)May 5, 2024 | fool.comGot $500? These Hot Growth Stocks Are Screaming Buys Right NowMay 2, 2024 | msn.comFirst FDA-approved cellular therapy for metastatic melanoma available in South FloridaMay 1, 2024 | globenewswire.comIovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024May 1, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Incyte (INCY) and Exelixis (EXEL)April 30, 2024 | globenewswire.comIovance Biotherapeutics to Present at Upcoming ConferencesApril 28, 2024 | fool.comWhere Will Iovance Biotherapeutics Stock Be in 5 Years?See More Headlines Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/14/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees557Year Founded2013Price Target and Rating Average Stock Price Target$24.64 High Stock Price Target$34.00 Low Stock Price Target$17.00 Potential Upside/Downside+123.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-444,040,000.00 Net Margins-23,615.70% Pretax Margin-23,872.37% Return on Equity-71.45% Return on Assets-55.17% Debt Debt-to-Equity RatioN/A Current Ratio4.63 Quick Ratio4.42 Sales & Book Value Annual Sales$1.90 million Price / Sales1,622.56 Cash FlowN/A Price / Cash FlowN/A Book Value$2.28 per share Price / Book4.84Miscellaneous Outstanding Shares279,833,000Free Float250,730,000Market Cap$3.09 billion OptionableOptionable Beta0.66 Social Links The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Frederick G. Vogt Esq. (Age 50)J.D., Ph.D., Interim CEO, President, General Counsel & Corporate Secretary Comp: $1.39MMr. Jean-Marc Bellemin M.B.A. (Age 51)CFO, Principal Accounting Officer & Treasurer Comp: $932.2kDr. Igor P. Bilinsky (Age 51)Chief Operating Officer Comp: $932.2kDr. Friedrich Graf Finckenstein M.D. (Age 57)Chief Medical Officer Comp: $1.06MMs. Sara PellegrinoVice President of Investor Relations & Public RelationsMs. Tracy WintonSenior Vice President of Human ResourcesMr. Howard B. Johnson M.B.A. (Age 64)Chief Business Officer Mr. James Ziegler M.B.A.Executive Vice President of CommercialDr. Raj K. Puri M.D.Ph.D., Executive VP of Regulatory Strategy & Translational MedicineMr. Brian Shew M.B.A.Senior VP & Head of Digital and Information TechnologyMore ExecutivesKey CompetitorsImmunovantNASDAQ:IMVTSpringWorks TherapeuticsNASDAQ:SWTXKrystal BiotechNASDAQ:KRYSCRISPR TherapeuticsNASDAQ:CRSPChina Biologic ProductsNASDAQ:CBPOView All CompetitorsInsiders & InstitutionsAmerican International Group Inc.Bought 2,941 shares on 5/14/2024Ownership: 0.042%CANADA LIFE ASSURANCE CoBought 20,778 shares on 5/14/2024Ownership: 0.016%Seven Eight Capital LPBought 174,402 shares on 5/13/2024Ownership: 0.062%Vanguard Group Inc.Bought 2,102,480 shares on 5/10/2024Ownership: 8.904%Roanoke Asset Management Corp NYSold 780 shares on 5/9/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions IOVA Stock Analysis - Frequently Asked Questions Should I buy or sell Iovance Biotherapeutics stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares. View IOVA analyst ratings or view top-rated stocks. What is Iovance Biotherapeutics' stock price target for 2024? 10 Wall Street analysts have issued 1 year price targets for Iovance Biotherapeutics' shares. Their IOVA share price targets range from $17.00 to $34.00. On average, they expect the company's share price to reach $24.64 in the next twelve months. This suggests a possible upside of 130.2% from the stock's current price. View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts. How have IOVA shares performed in 2024? Iovance Biotherapeutics' stock was trading at $8.13 on January 1st, 2024. Since then, IOVA stock has increased by 31.6% and is now trading at $10.70. View the best growth stocks for 2024 here. When is Iovance Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our IOVA earnings forecast. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.03. The biotechnology company had revenue of $0.72 million for the quarter, compared to analysts' expectations of $1.99 million. Iovance Biotherapeutics had a negative trailing twelve-month return on equity of 71.45% and a negative net margin of 23,615.70%. The firm's revenue for the quarter was up 71400.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.50) EPS. What ETFs hold Iovance Biotherapeutics' stock? ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Harbor Disruptive Innovation ETF (INNO), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), Xtrackers California Municipal Bond ETF (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX). Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.90%), Principal Financial Group Inc. (0.72%), Rice Hall James & Associates LLC (0.61%), Hennion & Walsh Asset Management Inc. (0.15%), Swiss National Bank (0.14%) and Sei Investments Co. (0.12%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IOVA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldThis 1 Biotech Stock has been shocking the marketsHuge AlertsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsREAD THIS – If You Missed Out On The AI BoomBanyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.